https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-10-01 / Breast 2009 Oct;18 Suppl 3:S51-4
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-10-01 / Breast 2009 Oct;18 Suppl 3:S51-42009-10-01 00:00:002019-02-15 08:50:12Immunizing against breast cancer: a new swing for an old sword
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-05-01 / Cancer Invest. 2009 May;27(4):361-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-05-01 / Cancer Invest. 2009 May;27(4):361-82009-05-01 00:00:002019-02-15 08:50:14Tumor vaccines for breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-01-01 / Cell. Immunol. 2009;257(1-2):23-31
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-01-01 / Cell. Immunol. 2009;257(1-2):23-312009-01-01 00:00:002019-02-15 08:50:13Autologous dendritic cells loaded with apoptotic tumor cells induce T cell-mediated immune responses against breast cancer in vitro
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-11-08 / Cancer Immunol. Immunother. 2009 Jun;58(6):887-900
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-11-08 / Cancer Immunol. Immunother. 2009 Jun;58(6):887-9002008-11-08 00:00:002021-11-15 17:03:25Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-09-27 / Surg. Today 2008;38(10):911-20
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-09-27 / Surg. Today 2008;38(10):911-202008-09-27 00:00:002008-09-27 00:00:00Effect of combined therapy with the antiestrogen agent toremifene and local hyperthermia on breast cancer cells implanted in nude mice
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-09-01 / J. Immunol. 2008 Sep;181(5):3690-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-09-01 / J. Immunol. 2008 Sep;181(5):3690-72008-09-01 00:00:002008-09-01 00:00:00Expression of a soluble TGF-beta receptor by tumor cells enhances dendritic cell/tumor fusion vaccine efficacy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-09 / Vaccine 2008 Aug;26(36):4716-24
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-09 / Vaccine 2008 Aug;26(36):4716-242008-07-09 00:00:002023-03-07 13:11:25Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-01 / J. Immunol. 2008 Jul;181(1):808-21
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-01 / J. Immunol. 2008 Jul;181(1):808-212008-07-01 00:00:002008-07-01 00:00:00Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-06-27 / BMC Immunol. 2008 Jun;9:32
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-06-27 / BMC Immunol. 2008 Jun;9:322008-06-27 00:00:002019-02-15 08:50:17Ex vivo recovery and activation of dysfunctional, anergic, monocyte-derived dendritic cells from patients with operable breast cancer: critical role of IFN-alpha
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-05-15 / Cancer Res. 2008 May;68(10):3854-62
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-05-15 / Cancer Res. 2008 May;68(10):3854-622008-05-15 00:00:002008-05-15 00:00:00Cancer immunotherapy using in vitro genetically modified targeted dendritic cells
